$240.80
▲ +0.5% Today
as of Jul 22, 16:46 ET
Last 30 days
Recent Press Releases & News
BMO Capital Initiates Axsome Therapeutics at Outperform With $310 Price Target
Axsome's NDA for AXS-12 in Narcolepsy Gets FDA Acceptance
Axsome Therapeutics Wins US FDA Review for Narcolepsy Drug Application
Overview
52-week range
$96
$242
99% of range
Avg surprise (last 3)
-1.2%
Avg reaction (last 2)
+6.1%
100% positive
Latest IV / EM
49%
EM ±11.1% · $240 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 4, 2026 | Mar/2026 | $-1.26 | $-0.85 | -48.2% | -57.5% | +8.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.94 | — | — | — | — | financials |
| Mon Aug 4, 2025 | Jun/2025 | $-0.92 | $1.00 | +8.0% | — | — | earnings |
| Mon May 5, 2025 | Mar/2025 | $-0.80 | $-1.26 | +36.5% | — | +3.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.34 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.67 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.44 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-1.32 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.54 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 10, 2026 | Jun/2026 | BMO | -$0.99 | -$0.92 | -7.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-63M | — | $-46M | $-37M | $-57M | — | $-63M | $-78M |
| Net income | $-65M | — | $-47M | $-48M | $-59M | — | $-65M | $-79M |
| EPS (diluted) | $-1.26 | — | $-0.94 | $-0.97 | $-1.22 | — | $-1.34 | $-1.67 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $305M | $323M | $325M | $303M | $301M | $315M | $327M | $316M |
| Inventory | $32M | $28M | $24M | $18M | $16M | $16M | $14M | $15M |
| Total current assets | $611M | $589M | $565M | $537M | $495M | $485M | $479M | $463M |
| Total assets | $714M | $690M | $669M | $640M | $597M | $568M | $561M | $548M |
| Long-term debt | $118M | $118M | $118M | $118M | $181M | $181M | $180M | $179M |
| Total liabilities | $659M | $602M | $596M | $567M | $543M | $511M | $469M | $445M |
| Total equity | $55M | $88M | $74M | $73M | $53M | $57M | $93M | $103M |